Abstract: A battery cell stack casing includes casing walls defining a housing interior for receiving a battery cell stack; a first end plate provided between the walls at a first end of the casing to close a first end of the housing interior. The casing also include a second end plate provided between the walls at a second end of the casing to close a second end of the housing interior. The casing walls have a multi-layer structure include: an inner layer having a first side facing into the housing interior and a second opposite side; an outer layer spaced outwardly from the second side of the inner layer; a thermally insulating volume defined between the second side of the inner layer and the outer layer, the thermally insulating material containing a low density thermally insulative material e.g., foam or other insulative material; and a layer of intumescent material provided on the first side of the inner layer.

Abstract: A battery cell stack casing includes casing walls defining a housing interior for receiving a battery cell stack, a first end plate provided between the walls at a first end of the casing to close a first end of the housing interior, and a second end plate provided between the walls at a second end of the casing to close a second end of the housing interior. The casing walls have a multi-layer structure that includes, an inner layer having a first side facing into the housing interior and a second opposite side, an outer layer spaced outwardly from the second side of the inner layer, an air or vacuum-filled thermally insulating volume defined between the second side of the inner layer and the outer layer, and a layer of intumescent material provided on the first side of the inner layer.

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPMT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.

Abstract: The invention relates to integration vectors for modifying a target genomic region comprising, in a 5? to 3? direction, a splice acceptor site, a 3? hybrid recognition site, and a marker sequence (i.e., a 5? gene trap vector); or alternatively comprising, in a 5? to 3? direction, a marker sequence; a 5? hybrid recognition site; and a splice donor site (i.e., a 3? gene trap vector). The integration vector, upon insertion into the target genomic region is capable of producing a recombinant RNA transcript that is comprised of a hybrid recognition site for a selection molecule. The hybrid recognition site of recombinant RNA produced from insertion of the 5? gene trap vector is comprised of a 5? hybrid recognition site derived from genomic sequence and a 3? hybrid recognition site derived from vector sequence.

Abstract: The present invention provides compositions and methods for enhancing RNA interference and facilitating the use of long RNA interference molecules. Accordingly, the invention includes a variety of novel applications of RNA interference, including methods related to screening RNA interference molecules using reporter genes to identify biological pathways, genes, therapeutic compounds and biomarkers.

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.

Abstract: A method for high-throughput genomics analysis, to identify the therapeutic or diagnostic utility of genes, entails the use of a construct to disrupt a gene or alleles of a gene in cells of interest. Arrays of such cells can be used to monitor such disrupted cells phenotypically in the context, for example, of testing drug candidates. Polynucleotides that comprise part of the disrupted genes can be recovered from such “knockout” cells, by virtue of an origin of replication or a host cell selection marker sequence that is part of the construct. The recovered polynucleotides can be used to identify the disrupted genes or to make homologous recombination vectors, which in turn can be employed to make multi-allele knockout cells. Double-stranded RNA molecules designed to target the recovered polynucleotide are used to downregulate the polynucleotide in vitro and in vivo, following determination of a therapeutically effective dosage of the RNAi molecule.